Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We discuss previous reports about vascular malformations in patients with Cowden syndrome and PTEN mutations.
|
27105569 |
2016 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
Dermatofibrosarcoma Protuberans in a Patient With Cowden Syndrome: Revisiting the PTEN and PDGF Pathways.
|
26488716 |
2016 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Due to the chromosome 10 deletion involving contiguous portions of BMPR1A and PTEN in our patient, he may be at risk for CS associated cancers and features, in addition to the polyps associated with JPS.
|
25846706 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
A PTEN mutation, c.1003C>T p.(Arg335Ter), was subsequently identified as the cause of Cowden syndrome in another family member (a nephew) with dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease), and genetic testing in the proband's daughter indicated that he was an obligate carrier of the mutation.
|
25756585 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Cowden syndrome-associated germline SDHD variants alter PTEN nuclear translocation through SRC-induced PTEN oxidation.
|
25149476 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN cause Cowden syndrome (CS), which increases lifetime risk of endometrial cancer.
|
26026735 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
We calculated the cost per mutation detected and analyzed the cost-effectiveness of performing selected PTEN testing among CS-like patients using a semi-quantitative score (the PTEN Cleveland Clinic [CC] score) compared with existing diagnostic criteria.
|
26169622 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline alterations in phosphatase and tensin homolog (PTEN; PTEN_mut+), succinate dehydrogenase B/C/D (SDHB-D; SDHx_var+), and killin (KLLN_Me+) cause CS and Cowden syndrome-like (CSL) phenotypes.
|
25376524 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Significantly increased KLLN promoter methylation was seen in CS individuals with and without a PTEN mutation/VUS compared with controls (P<0.001).
|
25669429 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline variants in SDHB/C/D (SDHx) genes account for subsets of CS/CS-like cases, conferring a higher risk of breast and thyroid cancers over those with only germline PTEN mutations.
|
25694510 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Clinical presentation of PTEN mutations in childhood in the absence of family history of Cowden syndrome.
|
25549896 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN, which encodes a widely expressed phosphatase, was mapped to 10q23 and identified as the susceptibility gene for Cowden syndrome, characterized by macrocephaly and high risks of breast, thyroid, and other cancers.
|
25916396 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
This case report illustrates the unusual presentation of Ewing sarcoma in a patient with PTEN-mutant CS, the probable underlying molecular pathogenesis, long-term management, and therapeutic considerations.
|
26553762 |
2015 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS) encompasses several rare disorders linked to mutations of the PTEN gene, including Cowden disease (CD) and Bannayan-Riley-Ruvalcaba syndrome (BRRS).
|
25170002 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To determine the prevalence of germline RASAL1 mutations in PTEN mutation-positive and wild type CS patients.
|
24712574 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Cowden syndrome is a rare condition resulting from a mutation in the tumor suppressor gene phosphatase and tensin homolog.
|
24838932 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Patients with CS with germline PTEN mutations are at higher risk for SMNs compared with the general population.
|
24778394 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In addition, the differential PTEN mutation status with corresponding LDD phenotypes suggests a potential correlation between germline or somatic mutation and coexisting LDD/CS or isolated LDD, respectively.
|
24102544 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN and p53 tumor suppressor cause Cowden syndrome and Li-Fraumeni syndrome, respectively.
|
24718924 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome.
|
24609522 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
PTEN gene analysis was performed and confirmed Cowden Syndrome, a rare genodermatosis with an autosomal dominant pattern of inheritance, characterized by multiple hamartomas.
|
24346879 |
2014 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutation analysis identified a deletion in exon 2, confirming the diagnosis of Cowden syndrome.
|
23512313 |
2013 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
PTEN mosaicism with features of Cowden syndrome.
|
23240978 |
2013 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PTEN gene are also found in patients with juvenile polyps and in Bannayan-Riley-Ruvalcaba syndrome and Cowden syndrome.
|
23599658 |
2013 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
Because loss of PTEN can activate mTOR and mTOR inhibitors are Food and Drug Administration approved to treat renal cell carcinoma, these agents have clinical potential in renal cell carcinoma associated with Cowden syndrome.
|
23764071 |
2013 |